| Literature DB >> 35177099 |
Abstract
BACKGROUND: Uniparental disomy (UPD) is well-known to be closely intermingled with imprinting disorders. Besides, UPD can lead to a disease by 'activation' of a recessive gene mutation or due to incomplete (cryptic) trisomic rescue. Corresponding to all common theories how UPD forms, it takes place as a consequence of a "chromosomic problem", like an aneuploidy or a chromosomal rearrangement. Nonetheless, UPD is rarely considered as a cytogenetic, but most often as a molecular genetic problem.Entities:
Keywords: Chromosome; Cytogenetics; Heterodisomy; Imprinting; Isodisomy; Mosaic; Uniparental disomy (UPD)
Year: 2022 PMID: 35177099 PMCID: PMC8851757 DOI: 10.1186/s13039-022-00585-2
Source DB: PubMed Journal: Mol Cytogenet ISSN: 1755-8166 Impact factor: 2.009
The by now known imprinting disorders are detailed acc. to the literature [8–10]
| Imprinting disorder | Gene(s) involved | Locus | Mosaic | Mechanisms | ||||
|---|---|---|---|---|---|---|---|---|
| UPD | Dup | Del | Imprinting center defect | Single nucleotide variant | ||||
| Transient neonatal diabetes mellitus (TNDM) (familial) | 6q24 | – | pat | 6q pat | – | + | + | |
| Birk-Barel intellectual disability syndrome (BBIDS) | 8q24 | – | – | – | – | – | + | |
| Silver-Russell syndrome (SRS) | 7 | – | mat | 7p and/or 7q mat | – | + | – | |
| 11p15.5 | + | mat | 11p mat | – | + | + | ||
| Beckwith-Wiedemann syndrome (BWS) | 11p15.5 | + | pat | 11p pat | – | + | + | |
| No syndrome yet but imprinting has been proven | 13q14.2 | – | mat | – | – | – | – | |
| Temple syndrome (TS14) | 14q32 | – | Mat | – | 14q pat | – | + | |
| Kagami-Ogata syndrome (KOS14) | 14q32 | + | pat | – | 14q mat | – | + | |
| (familial) Central Precocious Puberty (CPPB) | 14q32 | – | – | + | + | – | + | |
| Prader-Willi syndrome (PWS) | 15q11q13 | + | mat | – | 15q pat | – | + | |
| Angelman syndrome (AS) | 15q11q13 | + | pat | – | 15q mat | + | + | |
| Central Precocious Puberty 2 (CPPB2) | 15q11.2 | – | – | – | – | – | + | |
| Schaaf-Yang syndrome (SHFYNG) | 15q11.2 | – | – | – | – | – | + | |
| Pseudo-hypoparathyoridism type 1B (PHP1B) | 20q13 | + | pat | – | 20q mat | + | + | |
| Mulchandani-Bhoi-Conlin syndrome (MBCS) | n.a | 6q24 | – | mat | – | – | – | – |
| Multilocus imprinting disturbance (MLID) | They can show mixture of all above mentioned imprinting disorders or main features of only one of them | |||||||
All single-whole chromosome UPDs for which healthy carriers are reported; data acc. to Refs. [17, 18]
| Chromosome # | Uniparental disomy in healthy carrier reported | |||||
|---|---|---|---|---|---|---|
| Maternal | Paternal | Unclear | ||||
| [ | [ | [ | [ | [ | [ | |
| + | + | + | + | n.a | n.a | |
| + | + | + | + | + | n.a | |
| n.a | + | + | + | n.a | n.a | |
| + | + | n.a | + | + | n.a | |
| n.a | + | n.a | + | n.a | n.a | |
| ( +) | + | – | + | – | n.a | |
| – | + | – | + | – | n.a | |
| + | + | n.a | + | n.a | n.a | |
| + | + | + | + | n.a | n.a | |
| + | + | n.a | + | n.a | n.a | |
| – | – | – | [ +] | – | n.a | |
| ( +) | + | n.a | + | + | n.a | |
| + | + | + | + | + | n.a | |
| – | [ +] | – | [ +] | – | n.a | |
| – | [ +] | – | [ +] | – | n.a | |
| + | + | (+) | + | + | n.a | |
| + | + | (+) | + | n.a | n.a | |
| (+) | n.a | (+) | n.a | n.a | n.a | |
| n.a | n.a | n.a | + | + | n.a | |
| (+) | [+] | – | n.a | – | n.a | |
| + | + | + | + | + | n.a | |
| + | + | + | + | n.a | n.a | |
| + | + | + | + | + | n.a | |
| –* | n.a | (+*) | n.a | –* | n.a | |
– = no normal individuals available due to imprinting disorder; + = normal individuals reported; (+) = reported only in newborn; (+*) = reported only in male with two Y-chromosomes; –* = no reports as biologically not possible; [+] = should not exist—no data interpretation; imprint. disord. = imprinting disorder; n.a. = no reports available
Fig. 1Distribution of 4879 cases with maternal and paternal UPD and UPD cases in which parental origin was not determined is shown in A. In B only those 4530 UPD cases are summarized for which parental origin was determined. In C for all 4879 it is shown when a karyotype was provided
Fig. 23901 UPD cases with presumably normal karyotype are shown, and in how many of the cases a normal karyotype was indeed reported as 46,XX or 46,XY. This data is broken down by parental origin of the UPD
Fig. 3As before for Fig. 2, 3901 UPD cases with presumably normal karyotype are shown, and in how many of the cases a normal karyotype was indeed reported as 46,XX or 46,XY. This data is broken down for acrocentric and non-acrocentric chromosomal UPDs
Fig. 4Only those 1605 UPD cases are included for which a karyotype was reported as normal or abnormal. In A data is summarized in a pie chart and in B it is shown also separated by parental origin of the UPD
Fig. 5Karyotyping outcomes of acrocentric compared to non-acrocentric chromosomes based on 1455 cases are shown
Fig. 6UPD can be present in all body cells or as a mosaic of affected and non-affected cells. In A cases with mosaic are shown by chromosome and sorted according to percentage of reported cases with UPD-mosaic; in B the same results are provided in absolute numbers of reported cases
Fig. 7UPD frequencies by chromosomal origin according to this study [18] to a large single study [17]. In A results for all chromosomes are shown, in B only for those not being overrepresented in one of the two studies
Fig. 8Overall frequencies for chromosomal UPDs from this [18] and a large single study [17] are compared to those for chromosomal distribution of aneuploidies in first trimester abortions [20]
Checklist what optimally should be reported for each published UPD case
| Checklist what needs to be provided when reporting a UPD case | |
|---|---|
| Include if there is/are | Mention also |
| A clinical phenotype | Gender and age of patient |
| Isodisomy, heterodisomy or mixed iso-/heterodisomy | Test performed and if there are restrictions in those |
| A segmental, whole chromosome or several chromosomes affecting UPD | |
| A chromosomal aberration detectable as underlying cause of the UPD event | |
| A mosaic present | Which tissue(s) was/were studied |
| Variant (mosaic) conditions in different tissues | |
| Previous study in which the patient was already mentioned/published | If this cannot be completely excluded |
Ideally, when a UPD is reported it should be applied this checklist